|
1
|
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
|
AIDS
|
2010
|
2.85
|
|
2
|
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
|
J Acquir Immune Defic Syndr
|
2010
|
2.59
|
|
3
|
Chronic renal failure among HIV-1-infected patients.
|
AIDS
|
2007
|
2.07
|
|
4
|
The development of artificial neural networks to predict virological response to combination HIV therapy.
|
Antivir Ther
|
2007
|
1.71
|
|
5
|
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.
|
AIDS
|
2011
|
1.68
|
|
6
|
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
|
AIDS
|
2005
|
1.52
|
|
7
|
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
|
Artif Intell Med
|
2009
|
1.31
|
|
8
|
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
|
Expert Opin Pharmacother
|
2007
|
1.30
|
|
9
|
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
|
AIDS
|
2008
|
1.23
|
|
10
|
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
|
AIDS
|
2005
|
1.16
|
|
11
|
Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
|
J Med Virol
|
2008
|
1.02
|
|
12
|
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
|
AIDS
|
2004
|
0.96
|
|
13
|
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.
|
AIDS Patient Care STDS
|
2008
|
0.90
|
|
14
|
Deteriorating renal function and clinical outcomes in HIV-positive persons.
|
AIDS
|
2014
|
0.86
|
|
15
|
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.
|
AIDS
|
2013
|
0.86
|
|
16
|
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
|
AIDS
|
2012
|
0.85
|
|
17
|
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
|
Clin Infect Dis
|
2008
|
0.83
|
|
18
|
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study.
|
BMC Infect Dis
|
2012
|
0.82
|
|
19
|
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
|
Antivir Ther
|
2012
|
0.81
|
|
20
|
Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
|
AIDS
|
2013
|
0.81
|
|
21
|
A step ahead on the HIV collaboratory.
|
Science
|
2009
|
0.77
|
|
22
|
Management of late-presenting patients with HIV infection.
|
Antivir Ther
|
2010
|
0.75
|